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Psoriasis affects 1-2% of the population. In many patients the condition is mild and constitutes only a minor inconvenience. In a very few psoriasis can be so severe as to threaten life. In between these extremes lie the majority of sufferers for whom psoriasis is a great source of inconvenience and social embarrassment. For the most part treatment is by topical agents. Tar and dithranol preparations are effective, but usually produce the best results if patients are admitted to hospital. Often these agents are combined with ultraviolet radiation therapy, and in most patients plaque-type psoriasis clears in two to four weeks. Topical corticosteroid preparations are used widely. They are more acceptable to the patient than tar or dithranol because they do not stain. However some patients on potent fluorinated corticosteroids develop unstable psoriasis. The remission obtained with the aid of corticosteroids may be relatively short-lived (Seville 1976) . Also, excessive consumption of potent topical corticosteroids is attended by the risk of adrenocortical suppression from systemic absorption (Allen by et al. 1975 , Carruthers et al. 1975 , and by the risk of permanent skin atrophy. For those patients with very severe plaque-type psoriasis, generalized pustular psoriasis, or erythrodermic psoriasis, treatment with systemic cytotoxic drugs is usually effective. Methotrexate is the drug most often used for this purpose, but its recognized hepatotoxicity, even when it is given in optimal dosage, is cause for concern. The ideal treatment for psoriasis would avoid ointments but be safe and therefore applicable to the majority of patients with moderate psoriasis. It should preferably be an outpatient treatment, and should be effective in maintaining a prolonged remission.
Photochemotherapy for plaque-type psoriasis with oral psoralens The first major report of a new treatment for psoriasis came from Parrish and his colleagues (1974) who described the use of a photosensitizing drug called 8-methoxypsoralen (8-MOP) followed by exposure to longwave ultraviolet radiation for which they coined the term 'photochemotherapy'. The results in 21 adult caucasian patients with widespread plaque psoriasis was most impressive -all the patients cleared completely. Subsequent reports on greater numbers of patients have claimed similar impressive results , Melski et al. 1977 . Psoriasis cleared in 88% of 1308 patients with extensive psoriasis treated in the American Cooperative Clinical Trial, and failed to clear in only 3%. One percent abandoned treatment because of complications, and the remainder for reasons unconnected with treatment.
Psoralens belong to the heterocyclic group of compounds called furocoumarins, some of which are photosensitizing agents. Psoralens combine covalently with the pyrimidine bases of nucleic acids on irradiation at 365 nm. Cross-linkages between the two strands of DNA occur when psoralens, acting as bivalent reagents, combine with pyrimidine bases on opposite strands of the double helix (Cole 1970 , Dall'Acqua et al. 1971 . The molecular basis of these photoreactions has been reviewed by Scott et al. (1976) . The biological implications of these reactions with DNA, and with RNA and protein, are not fully understood. However, one recognized consequence in human skin is the inhibition of epidermal DNA synthesis (Walter et al. 1973 ) and therefore cell division. This inhibitory influence is one possible explanation of the effect of psoralens and longwave ultraviolet radiation on psoriasis which is characterized by an increased rate of epidermal cell turnover (Weinstein & Frost 1968 , Goodwin et at. 1974 .
The psoralen derivative which is most often used in photochemotherapy is 8-MOP. It is extracted commercially from the plant Ammi majus, and is usually supplied as 10 mg tablets. The recommended oral dose is approximately 0.6 mg/kg body weight. The metabolism of 8-MOP has been only partially investigated. Peak blood levels are usually reached within one to two hours after ingestion (Gazith & Schaefer 1977 , Steiner et at. 1977 , Thune & Volden 1977 , and the maximal photosensitivity of the skin occurs between two and three hours after administration. Exposure to ultraviolet radiation is therefore timed to coincide with this period. The drug is metabolized by the liver and excreted by the kidneys so that 90% of the ingested dose is eliminated within twelve hours .
Longwave ultraviolet radiation (320 to 400 nm, peak at 365 nm = UVA) is usually provided by banks of fluorescent lamps in stand-up booths or lie-down units. Treatment protocols are still under investigation, but the common aim is to produce repeated, controlled phototoxic reactions in the skin as frequently as is safely possible, usually at 48 hour intervals, until the rash clears, and then to reduce the frequency of treatment to a level which will maintain the remission. The success and safety of photochemotherapy demands accurate psoralen and UVA dosimetry, a subject which has been reviewed by . In the American Cooperative Clinical Trial (Melski et at. 1977) most patients cleared after 25 exposures and 12 weeks of therapy, exposures being given two to three times a week.
Photochemotherapy with oral psoralens offers many advantages to the patient. It avoids topical applications and is given on an outpatient basis. A cosmetically appealing tan develops. The success rate of photochemotherapy in plaque psoriasis is marginally better compared to that of dithranol, but the number of days required to clear the rash is approximately twice as long . Combination of photochemotherapy with topical steroids and dithranol (Gould & Wilson 1978 , Morison et al. 1978a or with an oral retinoic acid derivative ) may hasten the remission, but such combination therapies need further evaluation. Regular maintenance therapy at intervals of one to three weeks appears to decrease the relapse rate as compared to no maintenance therapy at all (Melski et at. 1977) . However, in this study, it did not prevent 50% of patients from flaring by one year, and this aspect of photochemotherapy needs further investigation. Hair shields the scalp from ultraviolet radiation so that scalp psoriasis, which is often of great concern to the patient, may not improve and must be treated by other conventional methods. Protection from further irradiation by natural ultraviolet radiation imposes certain restrictions on out-door activities in sunny weather on treatment days.
Known side effects
The short-term side effects are usually mild, respond to simple remedies, and rarely cause treatment to be abandoned. Excessive dryness of the skin responds to emollients. Pruritus occurs frequently and can be unpleasant, but usually settles after adjusting the dosage ofUVA, and oral antihistamines may provide further relief. Nausea from the 8-MOP tablets may be a problem, but is usually preventable by swallowing the tablets with food, or by taking the tablets in divided doses 2 and I t hours before exposure to UVA. It is rare for anti-emetics to be required. Excessive erythema, oedema and blisters are usually due to incorrect dosimetry. However, blisters occasionally develop on skin which is not excessively inflamed, and trauma, e.g. friction or pressure, sometimes plays a part in their development. Histologically the blisters are subepidermal. The basal cell layer bears the brunt of the damage, and cleft formation occurs first at this level (McGibbon & Vella Briffa 1978) . Persistent Koebner phenomenon may occur and very occasionally causes treatment to be abandoned. Other unusual side effects which may occur during photochemotherapy include photo-onycholysis , Zala et at. 1977 , acne (Jones & Bleehen 1977) , hirsutism , and labial herpes simplex. Thomsen & Schmidt (1977) reported the development of bullous pemphigoid in two patients during photochemotherapy. However, one patient had a previous history of the disease and the other was receiving sulphonamides, and it was not clear whether photochemotherapy was the only precipitating factor in these cases.
Potential side effects
Mutaqenicity and neoplastic potential: In contrast to the short-term side effects, the potential long-term effects are more serious. Of particular concern is the recognized mutagenic and carcinogenic potential. In the absence of ultraviolet radiation, 8-MOP can produce frameshift mutations in bacteria (Clarke & Wade 1975 , Bridges & Mottershead 1977 , Ashwood-Smith 1978 . However, this mutagenic potential is weak and resembles that of caffeine, which is not a carcinogenic compound. In the presence of UV A, psoralens produce mutagenic effects in various biological systems ranging from bacteriophages (Drake & McGuire 1967) to fungi (Scott & Alderson 1971) , bacteria (Mathews 1963 , Igali et al. 1970 , chinese hamster cel1s (Ashwood-Smith et al. 1977) , and human lymphocytes in culture (Swanbeck et al. 1975 , Carter et al. 1976 , Mourelatos et al. 1977 . Toda and his colleagues (1972) noted that topical psoralens and UV A produce an alteration in the number, size and distribution of melanosomes in the keratinocytes of Caucasian skin, suggesting the induction of a somatic mutation in the melanocytes. However, similar changes are not observed in humans during photochemotherapy with oral psoralens (Zaynoun et al. 1977) .
Intraperitoneal injection or topical application of8-MOP fol1owed by exposure to UVA has been shown to initiate skin tumour formation in rodents, especially in albino strains (Griffin et al. 1958 , Griffin 1959 , Urbach 1959 , Forbes & Urbach 1975 , Grube 1975 . The yield of tumours is much less when the psoralen is mixed with the diet, and Langner et al. (1977) failed to induce skin tumours in hairless albino mice when 8-MOP was administered by gavage.
Psoralens and sunlight have been used in herbal remedies for vitiligo for some 2000 years , and psoralens in purified tablet form have been used for the treatment of this disorder over the past twenty-five years (Lerner et al. 1953) with no apparent untoward effect. However, these patients have not been followed up closely enough to exclude serious long-term effects. Besides, treatment in these patients was usually in short spells of a few months, whereas patients with psoriasis may well need therapy for many years. Regular administration of ora18-MOP to individuals in outdoor occupations in sunny climates did not affect the incidence of skin cancer over a two-year period but the duration of this trial was too brief to allow an adequate assessment of the carcinogenic risk. To date, the only published evidence for carcinogenicity of 8-MOP and UVA in man comes from experiences in four patients with xeroderma pigmentosum (Reed 1976) and one patient with vitiligo with a previous history of arsenic ingestion (Moller & Howitz 1976) . All patients developed multiple skin cancers within months of starting photochemotherapy.
Other potential side effects 8-methoxypsoralen can be detected in the ocular lens after intraperitoneal injection in the rat (Lerman & Borkman 1977) , and cataracts can be produced in laboratory animals using intraperitoneal psoralens followed by UV A radiation (Cloud et al. 1960 (Cloud et al. , 1961 . The anatomical distribution of the injury corresponds to the extent of penetration of the UVA (Freeman & Troll 1969) , and therefore affects the cornea, anterior chamber, iris, and lens. Although cataracts have not been described in clinical practice, it is wise to protect the eyes with suitable goggles during the exposure to UV A and with suitable sun-glasses for at least twelve hours after ingestion of the tablets.
Up to 40 0 0 of UVA penetrates the epidermis (Everett et al. 1966) and therefore photochemotherapy may affect the photosensitized blood cells as they circulate through the superficial dermal vessels. Exposure of polymorphonuclear leukocytes to 8-MOP and UVA in vitro produces partial inhibition of chemotaxis (Langner & Christophers 1977) . Exposure of human lymphocytes to 8-MOP and UV A in vitro promotes sister chromatid exchanges in these cells (Carter et al. 1976 , Mourelatos et al. 1977 , Gaynor & Carter 1978 and also inhibits their expected proliferation after stimulation with PHA (Scherer et al. 1977) . During photochemotherapy in vivo T lymphocyte number and function is depressed transiently (Cormane et al. 1977 , Lischka et al. 1977 , Morison, Parrish & Bloch 1978 and platelet aggregation is also transiently impaired (Vella Briffa & Greaves 1979, in preparation) .
A preliminary investigation into the effects of long-term photochemotherapy on the elastic properties of the skin was conducted by Pierard (1978) and his colleagues. During a one-year follow-up period approximately 80% of 33 patients evolved towards increased extensibility and decreased restitution of the skin, while the remainder evolved towards decreased extensibility and increased restitution. Photochemotherapy may therefore be expected to induce dermal changes similar to those observed in actinic damage, contributing to the premature ageing of the skin.
Earlier reports of hepatotoxicity based on abnormal bromsulphthalein retention tests in two patients (Elliott 1959) have not been subsequently confirmed, although a transient rise in serum transaminase has been noted (Swan beck et al. 1975) , which may have been due to the concomitant ingestion of alcohol.
The teratogenic potential is unknown, and women in the reproductive age should be advised to practise effective contraception while receiving the treatment.
Photochemotherapy with topical psora lens Topical psoralens were used before oral psoralens for the treatment of plaque psoriasis, and some authors still recommend their use either exclusively or as an adjunct to oral psoralens to help clear stubborn plaques (Tronnier & Schule 1973 , Walter & Voorhees 1973 , Willis & Harris 1973 , Weber 1974 , Fischer & Alsins 1976 , Lakshmipathi et al. 1977 , Petrozzi et al. 1977 . Topical psoralens may be used in alcoholic solution, or in an emulsion or ointment base. The absorption of topical psoralens has been investigated by Kammerau et al. (1976) and Gazith et al. (1978) . The concentration of the psoralen and the nature of the vehicle influence the penetration and the photosensitizing capability (Suhonen 1976) , as can the interval between application and irradiation (Petrozzi et al. 1977) .
Photochemotherapy with topical psoralens suffers from certain disadvantages. It involves the patient applying the psoralen before the visit to the photochemotherapy unit, which is often inconvenient. It is more difficult to control treatment, and excessive erythema and blisters can easily occur. Patchy hyperpigmentation is produced which may last for many months. This may be avoided by applying the medication all over, but there is evidence that significant amounts of psoralen can be absorbed systemically in this way (Kammerau et al. 1976) . Topical psoralens therefore are not so convenient as oral psoralens, but they might be useful in very localized disease, and as an adjunct to oral psoralens in the treatment of resistant plaques.
Other applications of photochemotherapy Some workers have found photochemotherapy effective in erythrodermic psoriasis (Melski et al. 1977) although dosimetry is difficult and improvement slow. Complete clearing of skin lesions and relief of systemic symptoms was achieved in eight patients with generalized pustular psoriasis . Our own experience with oral photochemotherapy in erythrodermic psoriasis was not always satisfactory, and it did not compare favourably with methotrexate. Clearing with methotrexate and changing over to maintenance treatment with photochemotherapy may well prove the best approach in this situation.
The development of small portable units permits local irradiation of the palms, nails, and the soles which are inaccessible to ultraviolet radiation in stand-up units, and allows local treatment of limited plaque psoriasis elsewhere. Pustular psoriasis of the palms and soles can be successfully cleared in this way both with topical and with oral psoralens (Lakshmipathi et al. 1977 , Mizuno et al. 1976 , Morison et al. 1978c , Murray et al. 1979 , but in our experience psoriatic nail dystrophy and psoriatic arthropathy are not significantly improved.
Photochemotherapy can produce clinical and histological clearing of mycosis fungoides, especially in the early stages , Hjortshoj & Schmidt 1977 , Hodge et al. 1977 , Hofmann, Burg et al. 1977 , Roenigk 1977 , Bleehen et al. 1978 , Konrad et al. 1978 . Tumours respond only partially, and this is probably related to the limited depth of penetration of the ultraviolet radiation. Patients with advanced mycosis fungoides therefore often fail to respond satisfactorily to photochemotherapy on its own. It also remains to be seen whether the long-term prognosis of the disease is influenced by the institution of photochemotherapy in the early stages of its evolution. We also treated three patients with active Sezary syndrome (T-cell erythroderma). There was mild to moderate improvement of the rash and a decrease in the cellular infiltrate of the skin. However, pruritus -a most distressing symptom of the disease -was unaffected or increased, and the Sezary cell count in the blood remained unaffected.
Photochemotherapy of vitiligo is only moderately successful. In a study of 26 patients ), about 70% showed some improvement after more than twelve months of two to three exposures per week, suggesting that only highly motivated patients should embark on such therapy.
Although a satisfactory rationale is often lacking, photochemotherapy has been applied in limited clinical studies for the treatment of atopic eczema (Morison et al. 1978b) , seborrhoeic eczema (Dahl & Reymann 1977 ) urticaria pigmentosa (Christophers et al. 1978 , lichen planus (Ortonne et al. 1978) and alopecia areata (Weissmann et al. 1978) .
Conclusion
Photochemotherapy is an effective treatment for plaque-type psoriasis, pustular psoriasis of the palms and soles, and early mycosis fungoides. In the treatment of plaque-type psoriasis, photochemotherapy compares favourably with dithranol in terms of success rate, patient acceptability, ease of administration, and cost-effectiveness. However, its carcinogenic potential is cause for grave concern. Therefore, until the risk to humans is defined more clearly photochemotherapy cannot be recommended as an initial treatment for uncomplicated psoriasis, especially in the young. The use of photochemotherapy in other variants of psoriasis and skin diseases needs further investigation.
